SCHEMBL2893640

SCHEMBL2893640

C[C@H](COc1ccc(-n2ccc(OCc3ccc(Cl)cn3)cc2=O)cc1)N1CCCC1

nearest known ligand 0.54

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 16/20 0.54
KCNH2 Q12809 5/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13290279 1.00 MCHR1 (0.54) MCHR1KCNH2
SCHEMBL2892578 1.00 MCHR1 (0.54) MCHR1KCNH2
SCHEMBL13290270 0.85 MCHR1 (0.53) MCHR1KCNH2
SCHEMBL2890923 0.85 MCHR1 (0.53) MCHR1KCNH2
SCHEMBL2891164 0.85 MCHR1 (0.53) MCHR1KCNH2
SCHEMBL2895295 0.84 MCHR1 (0.51) MCHR1KCNH2
SCHEMBL2887453 0.84 MCHR1 (0.51) MCHR1KCNH2
SCHEMBL2893128 0.83 MCHR1 (0.74) MCHR1KCNH2
SCHEMBL2891241 0.83 MCHR1 (0.51) MCHR1KCNH2
SCHEMBL2891238 0.83 MCHR1 (0.51) MCHR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732456-B2 Pyridone derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-06-08 US claimed
US-20070208046-A1 Pyridone derivative MSD K.K. (JP) 2007-09-06 US claimed
EP-1741703-A1 PYRIDONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-01-10 EP claimed
US-7732456-B2 Pyridone derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-06-08 US disclosed
US-20070208046-A1 Pyridone derivative MSD K.K. (JP) 2007-09-06 US disclosed
EP-1741703-A1 PYRIDONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208046-A1 Pyridone derivative CHRM1, XDH, MTR MCHR1 535/4885KCNH2 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.